Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. [electronic resource]
Producer: 20090211Description: 563-72 p. digitalISSN:- 1533-4406
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Bevacizumab
- Capecitabine
- Cetuximab
- Colorectal Neoplasms -- drug therapy
- Deoxycytidine -- administration & dosage
- Disease-Free Survival
- ErbB Receptors -- antagonists & inhibitors
- Female
- Fluorouracil -- administration & dosage
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Mutation
- Neoplasm Metastasis -- drug therapy
- Organoplatinum Compounds -- administration & dosage
- Oxaliplatin
- Proto-Oncogene Proteins -- genetics
- Proto-Oncogene Proteins p21(ras)
- Quality of Life
- Treatment Failure
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
- ras Proteins -- genetics
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.